PLSE

Business Context and Reporting Period

Pulse Biosciences, Inc. (PLSE) is a bioelectric medicine company developing Nano-pulse Stimulation (NPS) technology for medical applications, primarily focusing on the treatment of atrial fibrillation (AF) and soft tissue ablation. The company operates as a single reportable segment. This summary covers the quarterly period ended June 30, 2024 (Q2 2024), and the six-month period ended June 30, 2024 (YTD 2024).

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no product revenues for the periods presented.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses increased by $1.5 million in Q2 2024 compared to Q2 2023. This was driven primarily by higher stock-based compensation (SBC) and increased compensation/employee-related costs in both R&D and G&A categories.
• Stock-Based Compensation: SBC expense rose significantly to $2.1 million in Q2 2024 from $1.1 million in Q2 2023, and $3.8 million YTD 2024 compared to $2.0 million YTD 2023.
• Cash Position: Cash and cash equivalents decreased by approximately $18.2 million during the first six months of 2024, compared to a decrease of $2.4 million in the same period in 2023. The 2023 period included significant financing inflows from warrant exercises that were not present in 2024.
• Interest Income: Net interest income increased to $0.8 million YTD 2024 from $0.1 million YTD 2023, largely due to the extinguishment of the 2022 Loan Agreement which eliminated interest expense.

Guidance, Outlook, and Management Commentary

• Strategic Focus: The company has shifted focus from dermatology to cardiology (atrial fibrillation) and soft tissue ablation. Commercial sales in dermatology have ceased, though support for existing users continues.
• Regulatory Milestones:
  • Received FDA 510(k) clearance in March 2024 for the CellFX nsPFA Percutaneous Electrode System for soft tissue ablation.
  • Received FDA Breakthrough Device Designation in July 2024 for the CellFX nsPFA Cardiac Surgery System.
  • Initiated first-in-human clinical studies for the cardiac clamp (Netherlands) and cardiac catheter (Czech Republic).
• Financing and Liquidity:
  • 2024 Rights Offering: Subsequent to the period end (July 3, 2024), the company closed a rights offering raising $60 million. Approximately 88% of the shares were purchased by Executive Chairman Robert W. Duggan, increasing his beneficial ownership to approximately 73%.
  • Runway: Management believes existing cash plus the proceeds from the rights offering will fund operations for at least the next 12 months.
• Risks: The company faces significant risks related to the need for additional capital, the uncertainty of clinical trial outcomes, regulatory approval timelines, and intense competition in the medical device sector. There is no assurance of future profitability.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the current cash burn rate (~$18M per six months) against the $60M raised in the subsequent rights offering.
• Majority Shareholder Influence: Confirm the implications of Robert W. Duggan's ~73% ownership on corporate governance and future capital raising strategies.
• Revenue Timeline: Assess the timeline for commercial revenue generation from the newly cleared Percutaneous Electrode System and the Cardiac Surgery System, given the cessation of dermatology sales.
• Stock-Based Compensation: Monitor the trajectory of SBC expenses, which have doubled year-over-year, and their impact on future dilution.
• Clinical Trial Progress: Track enrollment and data release from the ongoing first-in-human studies in the Netherlands and Czech Republic.